Find Reports

Select Report Type

Reimbursement Review

Displaying 126 - 150 of 1258

Please scroll or swipe to the right to view the full content.

Brand Name	Generic Name	Files	Therapeutic Area	Recommendation Type	Status	Submission Date	Recommendation Date Sort ascending	Project Number
Rinvoq	upadacitinib	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder feedback on Draft Recommendation	ankylosing spondylitis	Reimburse with clinical criteria and/or conditions	Complete	Oct 17, 2022	May 11, 2023	SR0759-000
Sohonos	palovarotene	Recommendation and Reasons Clinical, Pharmacoeconomic, Ethics, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Fibrodysplasia Ossificans Progressiva	Reimburse with clinical criteria and/or conditions	Complete	Oct 21, 2022	May 11, 2023	SR0761-000
Koselugo	selumetinib	Recommendation and Reasons Clinical, Pharmacoeconomic and Ethics combined Report Stakeholder feedback on Draft Recommendation	Neurofibromatosis type 1	Reimburse with clinical criteria and/or conditions	Complete	Oct 28, 2022	May 10, 2023	SR0764-000
Rukobia	fostemsavir	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder feedback on Draft Recommendation	Human immunodeficiency virus type 1 (HIV-1)	Reimburse with clinical criteria and/or conditions	Complete	Oct 28, 2022	May 10, 2023	SR0760-000
Carvykti	ciltacabtagene autoleucel	Recommendation and Reasons Clinical, Pharmacoeconomic, Ethics, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Relapsed or refractory multiple myeloma	Reimburse with clinical criteria and/or conditions	Complete	Sep 23, 2022	May 1, 2023	PG0302-000
Rylaze	crisantaspase recombinant	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder feedback on Draft Recommendation	Acute lymphoblastic leukemia	Reimburse with clinical criteria and/or conditions	Complete	Aug 18, 2022	Apr 26, 2023	PC0301-000
Camzyos	mavacamten	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder feedback on Draft Recommendation	Obstructive hypertrophic cardiomyopathy	Reimburse with clinical criteria and/or conditions	Complete	Sep 22, 2022	Apr 14, 2023	SR0755-000
Cablivi	caplacizumab	Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Acquired thrombotic thrombocytopenic purpura (aTTP)	Do not reimburse	Complete	Jun 7, 2022	Apr 5, 2023	SR0736-000
Opdivo	nivolumab	Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Resectable Non-Small Cell Lung Cancer	Reimburse with clinical criteria and/or conditions	Complete	Sep 13, 2022	Mar 30, 2023	PC0303-000
Tecartus	brexucabtagene autoleucel	Recommendation and Reasons Clinical, Pharmacoeconomic and Ethics combined Report Stakeholder feedback on Draft Recommendation	Acute lymphoblastic leukemia	Reimburse with clinical criteria and/or conditions	Complete	Sep 16, 2022	Mar 29, 2023	PG0304-000
Empaveli	pegcetacoplan	Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Paroxysmal nocturnal hemoglobinuria	Reimburse with clinical criteria and/or conditions	Complete	Aug 26, 2022	Mar 20, 2023	SR0748-000
Kerendia	finerenone	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder feedback on Draft Recommendation	Chronic kidney disease	Reimburse with clinical criteria and/or conditions	Complete	May 20, 2022	Mar 8, 2023	SR0737-000
Pluvicto	lutetium vipivotide tetraxetan	Recommendation and Reasons Clinical, Pharmacoeconomic, Ethics, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Metastatic castration-resistant prostate cancer	Reimburse with clinical criteria and/or conditions	Complete	Jul 21, 2022	Mar 3, 2023	PC0297-000
Rybrevant	amivantamab	Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Non-small cell lung cancer	Reimburse with clinical criteria and/or conditions	Complete	Apr 21, 2022	Mar 1, 2023	PC0289-000
Lynparza	olaparib	Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	gBRCAm, HER2-negative high-risk early breast cancer	Reimburse with clinical criteria and/or conditions	Complete	Aug 3, 2022	Mar 1, 2023	PC0299-000
Ultomiris	ravulizumab	Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Atypical hemolytic uremic syndrome	Reimburse with clinical criteria and/or conditions	Complete	Jun 8, 2022	Feb 27, 2023	SR0740-000
Orladeyo	berotralstat	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder feedback on Draft Recommendation	hereditary angioedema (HAE)	Reimburse with clinical criteria and/or conditions	Complete	Feb 22, 2022	Feb 17, 2023	SR0723-000
Oxlumo	lumasiran	Recommendation and Reasons Clinical, Pharmacoeconomic and Ethics combined Report Stakeholder feedback on Draft Recommendation	Primary hyperoxaluria type 1	Reimburse with clinical criteria and/or conditions	Complete	May 10, 2022	Feb 8, 2023	SR0734-000
Yescarta	axicabtagene ciloleucel	Recommendation and Reasons Clinical, Pharmacoeconomic and Ethics combined Report Stakeholder feedback on Draft Recommendation	Diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL)	Reimburse with clinical criteria and/or conditions	Complete	Jun 9, 2022	Feb 3, 2023	PG0293-000
Imfinzi	durvalumab	Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Biliary tract cancer	Reimburse with clinical criteria and/or conditions	Complete	Jul 14, 2022	Feb 3, 2023	PC0296-000
Keytruda	pembrolizumab	Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Advanced endometrial cancer	Reimburse with clinical criteria and/or conditions	Complete	Dec 15, 2021	Feb 3, 2023	PC0280-000
Dupixent	dupilumab	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder feedback on Draft Recommendation	Asthma	Reimburse with clinical criteria and/or conditions	Complete	Jun 28, 2022	Jan 20, 2023	SR0745-000
Saphnelo	anifrolumab	Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Systemic lupus erythematosus	Reimburse with clinical criteria and/or conditions	Complete	Jan 28, 2022	Jan 20, 2023	SR0717-000
Ferriprox	deferiprone	Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Transfusional iron overload	Reimburse with clinical criteria and/or conditions	Complete	Jun 8, 2022	Jan 19, 2023	SR0741-000
Benlysta	belimumab	Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Lupus nephritis	Reimburse with clinical criteria and/or conditions	Complete	Jul 7, 2022	Jan 19, 2023	SR0746-000

Health Technology Review

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 126 - 150 of 589

Please scroll or swipe to the right to view the full content.

Title	Description	Files	Last Updated Sort ascending	Project Sub Line	Status	Project Number
Intraocular Lenses for Cataract Surgery		Intraocular Lenses for Cataract Surgery	Nov 6, 2023	Rapid Review	Completed	RC1515-000
Anti–Vascular Endothelial Growth Factor Drugs for Age-Related Macular Degeneration		Anti–Vascular Endothelial Growth Factor Drugs for Age-Related Macular Degeneration	Nov 6, 2023	Rapid Review	Completed	RC1510-000
Supplemental Screening Modalities for People With Dense Breasts			Nov 1, 2023	Technology Review	Completed	HC0026-000
Refractive Laser Surgery for Vision Conditions		Refractive Laser Surgery for Vision Conditions	Oct 26, 2023	Rapid Review	Completed	RC1514-000
Cost-Effectiveness of Nirsevimab for Prevention of Respiratory Syncytial Virus Outcomes in Infants		Cost-Effectiveness of Nirsevimab for Prevention of Respiratory Syncytial Virus …	Oct 19, 2023	Technology Review	Completed	HE0045-000
Semaglutide 2 mg for Type 2 Diabetes		Semaglutide 2 mg for Type 2 Diabetes	Oct 19, 2023	Rapid Review	Completed	RC1507-000
Point of Care Ultrasound for Guided Central Venous Catheter Insertion		Point of Care Ultrasound for Guided Central Venous Catheter Insertion	Oct 16, 2023	Rapid Review	Completed	RC1509-000
Post–COVID-19 Condition Treatment and Management: Rapid Living Scoping Review			Oct 12, 2023	Scoping Review	Living Review	RE0040-000/RE0040-004
Radiofrequency Ablation for Chronic Knee, Hip, and Shoulder Pain		Radiofrequency Ablation for Chronic Knee, Hip, and Shoulder Pain	Oct 11, 2023	Rapid Review	Completed	RC1504-000
IV Acetaminophen for Acute Pain in Emergency Departments		IV Acetaminophen for Acute Pain in Emergency Departments	Oct 6, 2023	Rapid Review	Completed	RC1508-000
Drug Shortages in Canada — Expert Panel			Oct 5, 2023	Technology Review	In Progress	HC0074-000
Perspectives and Experiences Regarding the Impacts of Emergency Department Overcrowding		Perspectives and Experiences Regarding the Impacts of Emergency Department Over…	Sep 28, 2023	Technology Review	Completed	HC0067-000
Optimizing the Use of Iodinated Contrast Media: Conservation Strategies Used Across Canada During the 2022 Shortage		CM0001-ICM-Conservation-Strategies.pdf	Sep 20, 2023	CMII Service	Completed	CM0001-000
Direct-Acting Antivirals for Pediatric Chronic Hepatitis C Virus Infection		Direct-Acting Antivirals for Pediatric Chronic Hepatitis C Virus Infection	Sep 20, 2023	Rapid Review	Completed	RC1502-000
Midline and Extended Dwell Catheters for IV Antibiotics		Midline and Extended Dwell Catheters for IV Antibiotics	Sep 18, 2023	Rapid Review	Completed	RC1505-000
Non-Sterile Glove Use		Non-Sterile Glove Use	Sep 15, 2023	Rapid Review	Completed	RC1499-000
Somatropin for Short Stature		Somatropin for Short Stature	Sep 15, 2023	Rapid Review	Completed	RC1501-000
Remdesivir (Veklury) for the Treatment of COVID-19 in the Inpatient Setting		Summary Report — September 2023 Systematic Review — September 2023	Sep 13, 2023	Systematic Review	Completed	RE0048-000
Tocilizumab (Actemra) for the Treatment of Hospitalized Patients With COVID-19		Systematic Review — September 2023 Summary Report — September 2023	Sep 13, 2023	Systematic Review	Completed	RE0049-000
Nirmatrelvir-Ritonavir (Paxlovid) for the Treatment of COVID-19		Systematic Review, September 2023 Summary Report, September 2023	Sep 12, 2023	Health Technology Assessment	Completed	HT0042-000
Remdesivir (Veklury) for the Treatment of COVID-19 in the Outpatient Setting		Systematic Review — September 2023 Summary Report — September 2023	Sep 12, 2023	Health Technology Assessment	Completed	HT0041-000
Timing of Ventilator Circuit Tubing Replacement		Timing of Ventilator Circuit Tubing Replacement	Sep 8, 2023	Rapid Review	Completed	RC1498-000
Telephone Triage Services	Telephone triage programs provide timely access to trained health care professionals who can assess a patient’s symptoms over the phone and provide self-care advice or referral to an appropriate level of care.	canadian_telephone_triage_programs_infographic.pdf Telephone Triage Services	Sep 7, 2023	Environmental Scan	Completed	ES0378-000
Prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC)		Implementation Advice	Aug 30, 2023	Technology Review	Completed	HC0060-000
Transcatheter Edge-To-Edge Valve Repair for Tricuspid Regurgitation		Transcatheter Edge-To-Edge Valve Repair for Tricuspid Regurgitation	Aug 22, 2023	Rapid Review	Completed	RC1500-000

Horizon Scan

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 101 - 111 of 111

Projects in Progress

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 26 - 40 of 40

View All Reports

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 126 - 150 of 2093

Please scroll or swipe to the right to view the full content.

Title	Files	Last Updated Sort ascending	Project Line	Project Sub Line	Status	Project Number
eplontersen	Recommendation and Reasons Patient and Clinician Group Input	Dec 20, 2024	Reimbursement Review		Active	SR0826-000
inclisiran	Recommendation and Reasons Clinical and Pharmacoeconomic Combined Report Feedback on Draft Recommendation Patient and Clinician Group Input	Dec 20, 2024	Reimbursement Review		Complete	SR0791-001
inclisiran	Recommendation and Reasons Clinical and Pharmacoeconomic Combined Report Feedback on Draft Recommendation Patient and Clinician Group Input	Dec 20, 2024	Reimbursement Review		Complete	SR0791-000
avapritinib	Recommendation and Reasons Patient and Clinician Group input	Dec 20, 2024	Reimbursement Review		Active	PC0335-000
Multiple Myeloma	Scoping Document	Dec 19, 2024	Reimbursement Review	Provisional Funding Algorithm	Active	PH0068-000
blinatumomab	Patient and Clinician Group input	Dec 19, 2024	Reimbursement Review		Active	PC0365-000
durvalumab	Patient and Clinician Group input	Dec 17, 2024	Reimbursement Review		Active	PC0389-000
belzutifan	Patient and Clinician Group Input	Dec 17, 2024	Reimbursement Review		Active	PC0386-000
pembrolizumab	Patient and Clinician Group Input	Dec 17, 2024	Reimbursement Review		Active	PC0387-000
leuprolide mesylate	Patient and Clinician Group Input	Dec 17, 2024	Reimbursement Review		Active	PC0370-000
danicopan	Recommendation and Reasons Patient and Clinician Group Input	Dec 17, 2024	Reimbursement Review		Active	SR0815-000
Brentuximab vedotin	Recommendation and Reasons Clinical and Pharmacoeconomic Combined Report Feedback on Draft Recommendation Patient and Clinician Group Input	Dec 17, 2024	Reimbursement Review		Complete	PC0371-000
enfortumab vedotin	Recommendation and Reasons Patient and Clinician Group Input	Dec 17, 2024	Reimbursement Review		Active	PC0353-000
Antiviral Drugs for the Treatment of Suspected or Confirmed Influenza A or Influenza B		Dec 16, 2024	Health Technology Review	Systematic Review	In Progress	RE0052-000
relugolix, estradiol, and norethindrone acetate		Dec 16, 2024	Reimbursement Review		Pending	SR0885-000
Icatibant Implementation Advice Panel	Implementation Advice for Icatibant	Dec 16, 2024	Health Technology Review	Technology Review	Completed	HC0097-000 - SX0849-000
donanemab	Patient and Clinician Group input	Dec 16, 2024	Reimbursement Review		Suspended	SR0857-000
lecanemab	Patient and Clinician Group input	Dec 16, 2024	Reimbursement Review		Suspended	SR0822-000
atogepant	Recommendation and Reason Clinical and Pharmacoeconomic Combined Report Feedback on Draft Recommendation Patient and Clinician Group input	Dec 16, 2024	Reimbursement Review		Complete	SR0817-000
Emerging Antiviral Drugs to Prevent or Treat Influenza	Emerging Antiviral Drugs to Prevent or Treat Influenza	Dec 16, 2024	Horizon Scan	Emerging Health Technologies	Completed	EH0128-000
sotatercept	Recommendation and Reasons Patient and Clinician Group Input	Dec 16, 2024	Reimbursement Review		Active	SR0828-000
pembrolizumab	Patient and Clinician Group Input	Dec 13, 2024	Reimbursement Review		Active	PC0383-000
guselkumab		Dec 13, 2024	Reimbursement Review		Pending	SR0882-000
belumosudil	Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Dec 13, 2024	Reimbursement Review		Complete	SR0789-000
Endometrial cancer	Proposed Scope	Dec 12, 2024	Reimbursement Review	Provisional Funding Algorithm	Open for Stakeholder Input	PH0066-000